Please assess the completion status of the following clinical trial:

Trial Title: Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Active SLE disease，and at least according with 4 of the 11 items of the American College of Rheumatology (ACR) criteria 1997.~* Age \& Gender: Male or female between 18 and 65 years of age inclusive，and the sex ratio is not limited~* Signed informed consent form，willing or able to participate in all required study evaluations and procedures.~* SELENA-SLEDAI(Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index) score ≥ 8 during the screening period.and if there is hypocomlement or the Anti-dsDNA score, SELENA-SLEDAI disease activity score should be at least 6 at screening .~* Autoantibody-positive~* on a stable SLE treatment regimen for at least 30 days prior to Day 1, which consisted of any of the following (alone or in combination): cortical hormone,anti-malarials,non-steroidal anti inflammatory drugs (NSAIDs),or any immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin ).~Exclusion Criteria:~* Severe lupus nephritis within two months(designed as:Urine protein\>6g/24h or serum creatinine ( SCr）\>2.5mg/dL or 221umol/L ) or needing for hemodialysis or recepting high dose cortical hormone ≥14 days( metacortandracin\>100mg/d or equivalent)~* Central nervous system disease caused by SLE or non SLE within two months (including epilepsy， mental disease，organic encephalopathy syndrome，cerebrovascular accident, encephalitis, central nervous system vasculitis）;~* there are serious heart, liver, kidney and other important organs and blood, endocrine system diseases and medical history;~Evaluation criteria for severity :~1. Alanine aminotransferase（ALT）or aspartate aminotransferase (AST) ≥2 upper limit of normal (ULN);~2. Creatinine Clearance (Ccr)\<30ml/min;~3. White Blood Cell Count(WBCs)\<2.5x 10(9)/L;~4. hemoglobin\<85g/L;~5. Platelets\<50x 10(9)/L.~   * Have a historically active hepatitis or active hepatitis or medical history,hepatitis B :Patients with positive HBsAg are excluded.;Hepatitis C: Patients with hepatitis C antibody positive are excluded;~  * Immune deficiency, uncontrolled severe infection and patients with active or recurrent peptic ulcer;~  * Pregnant , lactating women and men or women who have birth plans in the past 12 months ;~  * Have a history of allergic reaction to human biological medicines.~  * Receipt of live vaccine within 1 month;~  * Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the elderly).~  * Have received treatment with B cell targeted therapy such as Rituximab or Epratuzumab etc.~  * Receipt of anti-tumor necrosis factor、interleukin receptor antagonist；~  * Receipt of IV immunoglobulin（IVIG）,prednisone\>100mg/d more than 14 days or plasma exchange;~  * There are active infections (such as herpes zoster, human immunodeficiency virus (HIV) virus infection, active tuberculosis, etc.) during the screening period;~  * Patients have depression or the significant suicide ideation;~  * Investigator considers candidates not appropriating for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo SC plus standard therapy; placebo once weekly ,and total of 48 doses
- RC18 80 mg plus standard therapy (Type: EXPERIMENTAL): RC18 80 mg/kg SC plus standard therapy RC18 80 mg SC once weekly X 48 doses
- RC18 160 mg plus standard therapy (Type: EXPERIMENTAL): RC18 160 mg/kg SC plus standard therapy RC18 160 mg SC once weekly X 48 doses
- RC18 240 mg plus standard therapy (Type: EXPERIMENTAL): RC18 240 mg/kg SC plus standard therapy RC18 240 mg SC once weekly X 48 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete